Powder: -20°C for 3 years | In solvent: -80°C for 1 year
S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 13,000 | |||
10 mg | 在庫あり | ¥ 19,500 | |||
25 mg | 在庫あり | ¥ 39,500 | |||
50 mg | 在庫あり | ¥ 64,000 | |||
100 mg | 在庫あり | ¥ 104,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 14,000 |
説明 | S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research. |
ターゲット&IC50 | AKR1C3:3.04 nM |
In vitro |
S19-1035 demonstrates low cytotoxicity (0-100 μM ; 72 h or 96 h) and limited antitumor efficacy when used alone.[1] S19-1035 significantly reverses the resistance of doxorubicin-resistant breast cancer cell lines when administered at 10 μM for 8 days.[1] |
In vivo | Setrobuvir (200, 400, and 800 mg) BID were -2.1, -2.2, and -2.9 log10 IU/mL, respectively (vs ≤0.1 log10 IU/mL with placebo).[3] |
分子量 | 356.80 |
分子式 | C19H17ClN2O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (315.3 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
S19-1035 Metabolism NADPH Inhibitor inhibitor inhibit